期刊文献+

不同剂量氟伐他汀对冠心病患者瘦素、脂联素的影响 被引量:6

Effect of different doses fluvastatin on leptin and adiponectin in patients with coronary heart disease
暂未订购
导出
摘要 目的:探讨瘦素、脂联素在冠心病发病过程中的作用以及氟伐他汀用于治疗冠心病的理想剂量。方法:将住院确诊为冠心病的160例患者随机分成两组,每组80例,均在冠心病常规治疗的基础上服用氟伐他汀。第1组口服常规剂量40 mg/d,第2组口服强化剂量80 mg/d。分别于治疗前和治疗2个月后测定两组患者血清瘦素、脂联素的浓度。同时设第3组为健康对照组。结果:与治疗前相比,服用氟伐他汀2个月后,两组患者总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-c)、C反应蛋白(CRP)和血清瘦素水平均明显降低(均P<0.05),高密度脂蛋白胆固醇(HDL-c)、血清脂联素水平均较治疗前明显升高(均P<0.05);与常规降脂组相比,强化降脂组TC、LDL-c下降幅度和HDL-c升高幅度更明显(均P<0.05),而TG、CRP、瘦素水平降低幅度,脂联素水平升高幅度,两组之间无较大差异(均P>0.05)。结论:血清瘦素、脂联素与冠心病密切相关。氟伐他汀可显著降低冠心病患者瘦素水平,升高脂联素水平,并且与常规降脂治疗相比,强化降脂治疗能够提供更好的保护作用。 Objective: To investigate the role of leptin and adiponectin in pathogenesis of coronary heart disease(CHD) and the ideal doses of fluvastatin for treating CHD.Methods: 160 patients with CHD were randomly divided into two groups(80 cases in each group),and all of them were taken fluvastatin on the conventional therapy of CHD.Group 1 of conventional lipid-lowering group,40 mg,daily;group 2 of intensive lipid-lowering group,80 mg,daily.The concentrations of leptin and adiponectin were detected respectively before treatment and two months after treatment.Group 3 was healthy control group.Results: Compared with before treatment,TC,TG,LDL-c,CRP and serum leptin were significantly decreased in both group 1 and 2 after two months(P0.05),whereas HDL-c,adiponectin were significantly increased in these two groups(P0.05).Compared with the conventional lipid-lowering group,the intensive lipid-lowering group had more lower levels of TC,LDL-c and more higher levels of HDL-c(P0.05),although they had the same levels of TG,CRP,serum leptin and adiponectin(P0.05).Conclusion: There is a significant association between serum leptin and adiponectin with CHD.Fluvastatin can reduce serum leptin and elevate adiponectin significantly,and intensive lipid-lowering therapy can provide better protection than conventional lipid-lowering therapy.
出处 《天津医科大学学报》 2012年第1期53-56,共4页 Journal of Tianjin Medical University
基金 天津市卫生局科技基金资助项目(2011K258)
关键词 冠心病 氟伐他汀 瘦素 脂联素 coronary heart disease fluvastatin leptin adiponectin
  • 相关文献

参考文献2

二级参考文献1

共引文献155

同被引文献55

  • 1刘岩,邹大进,李慧,陈月,丁继军,郑兴,郭鹏飞.低脂联素血症是冠状动脉粥样硬化严重程度的重要标志[J].中华内分泌代谢杂志,2005,21(1):5-8. 被引量:112
  • 2郁志明,杨志健,张笛,洪侃.降脂治疗对冠心病患者脂联素水平的影响[J].江苏医药,2006,32(9):887-887. 被引量:5
  • 3吕青山,谢秀梅,陈晓彬,谢晓华,孙国举.瘦素水平与冠心病及其相关危险因素的关系[J].医学临床研究,2006,23(12):1914-1916. 被引量:2
  • 4尹炯,潘晓明,蒲红,吴宗贵,刘春.冠心病患者血浆脂联素水平降低[J].中华高血压杂志,2007,15(8):685-686. 被引量:13
  • 50pstad TB,Pettersen A,Arnesen H,et al. The co-exis- tence of the IL-18 +183 A/G and MMP-9 -1562 C/T poly- morphisms is associated with clinical events in coronary artery disease patients[J]. PLoS One, 2013,8 (9) : e74498.
  • 6Springall R, Amezcua-Guerra LM, Gonzalez-Pacheco H, et al. Interferon-gamma increases the ratio of matrix met- alloproteinase-9/tissue inhibitor of metalloproteinase-1 in peripheral monocytes from patients with coronary arterydisease[J]. PLoS One, 2013,8 (8) : e72291.
  • 7Hsu TW,Kuo KL,Hung SC,et al. Progression of kidney- disease in non-diabetic patients with coronary artery dis- ease: predictive role of circulating matrix metallopro- teinase-2, -3, and -9[J]. PLoS One,2013,8(7) :e70132.
  • 8Xu X,Wang L,Xu C,et al. Variations in matrix metallo- proteinase-1,-3, and -9 genes and the risk of acute coro- nary syndrome and coronary artery disease in the Chinese Han population[J]. Coron Artery Dis, 2013,24 (4) : 259-265.
  • 9Golovkin AS,Matveeva VG,Grigor'ev EV,et al. Postop- erative dynamic changes in matrix metalloproteinase lev- els in patients with coronary artery bypass graft proce- dure complications[J]. Kardiologiia,2012,52(9):4-7.
  • 10Hou ZH, Lu B, Gao Y, et al. Matrix metalloproteinase-9 (MMP-9) and myeloperoxidase(MPO) levels in patients with nonobstructive coronary artery disease detected by coronary computed tomographic angiography[J]. Acad Ra- diol, 2013,20 ( 1 ) : 25 -31.

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部